Literature DB >> 10576528

Strategies for better diabetes control in the US.

A J Garber1.   

Abstract

Recent surveys in the US have indicated that 71% of the total diabetes care is delivered by primary care physicians, and that current management practices in terms of the point of initiation of pharmacological treatment fall considerably short of the American Diabetes Association's recommendations. In part, this delay in initiating treatment is due to a fear of provoking hypoglycaemia, which in itself results from a general avoidance of blood glucose monitoring on the part of patients. As a consequence of this apparent disregard for diabetes care, blood glucose concentrations are not adequately controlled in the US and this is reflected in a high incidence of chronic complications, particularly diabetic neuropathy. This is likely to have major cost implications in the future. In an effort to improve the standard of diabetes care, a number of US authorities have begun producing guidelines for primary care physicians, and in the State of Texas, treatment algorithms that incorporate recommendations based on the current US registration trial data have been developed. These recommendations, which have now been adopted by the State of Texas and form part of the minimum standard of care mandated by the State Department of Health's Diabetes Council, provide guidance on the selection and use of oral antidiabetic drugs (including sulphonylureas, metformin, troglitazone, repaglinide and acarbose) in patients with type 2 diabetes, both for glycaemic control and for prevention of cardiovascular complications. It is hoped that organised implementation of these treatment algorithms will produce better control of diabetes and its complications than the current ad hoc strategies used by individual practitioners.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10576528     DOI: 10.2165/00003495-199958001-00014

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  13 in total

1.  Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.

Authors:  S Kumar; A J Boulton; H Beck-Nielsen; F Berthezene; M Muggeo; B Persson; G A Spinas; S Donoghue; S Lettis; P Stewart-Long
Journal:  Diabetologia       Date:  1996-06       Impact factor: 10.122

Review 2.  Troglitazone: a review of its use in the management of type 2 diabetes mellitus.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

3.  Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy.

Authors:  Y Iwamoto; K Kosaka; T Kuzuya; Y Akanuma; Y Shigeta; T Kaneko
Journal:  Diabetes Care       Date:  1996-02       Impact factor: 19.112

Review 4.  Repaglinide.

Authors:  J A Balfour; D Faulds
Journal:  Drugs Aging       Date:  1998-08       Impact factor: 3.923

5.  Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

Authors:  A J Garber; T G Duncan; A M Goodman; D J Mills; J L Rohlf
Journal:  Am J Med       Date:  1997-12       Impact factor: 4.965

6.  Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study.

Authors:  R F Coniff; J A Shapiro; D Robbins; R Kleinfield; T B Seaton; P Beisswenger; J B McGill
Journal:  Diabetes Care       Date:  1995-06       Impact factor: 19.112

7.  Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.

Authors:  V A Fonseca; T R Valiquett; S M Huang; M N Ghazzi; R W Whitcomb
Journal:  J Clin Endocrinol Metab       Date:  1998-09       Impact factor: 5.958

Review 8.  Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus.

Authors:  C J Dunn; D H Peters
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

9.  Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.

Authors:  R F Coniff; J A Shapiro; T B Seaton; G A Bray
Journal:  Am J Med       Date:  1995-05       Impact factor: 4.965

Review 10.  Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus.

Authors:  J A Balfour; D McTavish
Journal:  Drugs       Date:  1993-12       Impact factor: 9.546

View more
  1 in total

Review 1.  Gliclazide modified release.

Authors:  Jane K McGavin; Caroline M Perry; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.